Skip to main content

and
  1. Article

    Open Access

    Antibodies elicited by the first non-viral prophylactic cancer vaccine show tumor-specificity and immunotherapeutic potential

    MUC1 is a shared tumor antigen expressed on >80% of human cancers. We completed the first prophylactic cancer vaccine clinical trial based on a non-viral antigen, MUC1, in healthy individuals at-risk for colon...

    Jason J. Lohmueller, Shuji Sato, Lana Popova, Isabel M. Chu in Scientific Reports (2016)